H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on Nanobiotix (0QAV – Research Report) today and set a price target of €10.00.
Swayampakula Ramakanth has given his Buy rating due to a combination of factors including positive clinical data and strategic partnerships. The recent data from Nanobiotix’s Phase 1 study of NBTXR3 in second-line NSCLC treatment showed promising survival rates, surpassing historical controls. This suggests a potential for NBTXR3 to offer a more effective treatment option for patients who typically have limited therapeutic choices.
Additionally, the combination therapy involving NBTXR3 with immune checkpoint inhibitors in Study 1100 demonstrated notable efficacy, particularly in ICI-naïve patients, and was well-tolerated. These clinical advancements, coupled with the ongoing collaboration with Janssen Pharmaceuticals for the Phase 2 CONVERGE study, bolster confidence in the company’s future prospects. Furthermore, the valuation analysis supports a €10.00 price target, reflecting a positive outlook on the company’s financial trajectory.
Ramakanth covers the Healthcare sector, focusing on stocks such as Eton Pharmaceuticals, AbSci, and Vericel. According to TipRanks, Ramakanth has an average return of -1.3% and a 31.06% success rate on recommended stocks.
In another report released on March 28, Stifel Nicolaus also maintained a Buy rating on the stock with a €16.00 price target.